Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | First-in-human bispecific CAR T-cell therapy for R/R non Hodgkin lymphoma

Nirav Niranjan Shah • 27 Mar 2019
EBMT 2019
Lymphoma Non-Hodgkin Lymphoma CAR-T

Nirav Niranjan Shah, MD, from the Medical College of Wisconsin, Milwaukee, WI, delivers updates from the first-in-human Phase I dose-escalation study of bispecific anti-CD19, anti-CD20 CAR T-cells (CAR-20.19-T) for relapsed/refractory non-Hodgkin Lymphoma (NCT03019055). Dr Shah was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

More from Nirav Niranjan Shah

2:42
Dual-targeted anti-CD19/anti-CD20 CAR T-cells in R/R MCL: insights from a Phase I/II trial
Nirav Niranjan Shah • 11 Dec 2023
1:35
Pirtobrutinib in R/R FL: results from the BRUIN study
Nirav Niranjan Shah • 11 Dec 2023
Novel therapies in NHL: BTK inhibitors & degraders
Nirav Niranjan Shah et al. • 17 Oct 2023
2:13
Phase II trial of split-dose R-CHOP for older patients with DLBCL
Nirav Niranjan Shah • 4 Jun 2023

Related Videos

1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals